Drug Profile
Darbepoetin alfa biosimilar - Nichi-Iko Pharmaceutical/Aprogen
Alternative Names: AP 032Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Aprogen; Nichi-Iko Pharmaceutical
- Developer Nichi-Iko Pharmaceutical
- Class Antianaemics; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anaemia
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for research development in Anaemia in Japan (SC, Injection)
- 12 May 2015 Nichi-Iko plans a clinical trial for Anaemia in Japan (Nichi-Iko website, May 2015)
- 12 May 2015 Early research in Anaemia in Japan (SC)